LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 133

Search options

  1. Article ; Conference proceedings: Symposium Advances in Medical Oncology

    Aggarwal, Shyam

    [circa 2003]

    2003  

    Institution Symposium Advances in Medical Oncology
    Author's details Shyam Aggarwal, guest ed
    Language English
    Publishing country India
    Document type Article ; Conference proceedings
    Note In: Journal / International Medical Science Academy. - ISSN 0971-071X. - 16 (2003),2, S. 83 - 109
    HBZ-ID HT013878410
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 3757 -16- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Adverse effects of immuno-oncology drugs-Awareness, diagnosis, and management: A literature review of immune-mediated adverse events.

    Aggarwal, Shyam

    Indian journal of cancer

    2019  Volume 56, Issue Supplement, Page(s) S10–S22

    Abstract: Immuno-oncology (IO) approaches such as cytokine therapy, immune-checkpoint blockers (ICBs), cancer vaccines, and cell-based therapies have revolutionized cancer treatment. ICBs provide better response-to-toxicity profile among various IO approaches; ... ...

    Abstract Immuno-oncology (IO) approaches such as cytokine therapy, immune-checkpoint blockers (ICBs), cancer vaccines, and cell-based therapies have revolutionized cancer treatment. ICBs provide better response-to-toxicity profile among various IO approaches; however, they can cause dysregulation of host immune system resulting in immune-mediated adverse events (imAEs). The skin and gastrointestinal system are most commonly affected. Although reversible, imAEs may cause life-threatening conditions if untreated. Risk assessment and appropriate patient selection before treatment initiation may prevent most imAEs. Key factors in effectively managing imAEs include baseline clinical evaluation, appropriate diagnostic tests, severity grading, timely decision on discontinuation or reintroduction of ICB treatment, and intervention with immunosuppressive and/or immunomodulatory agents. Patient and healthcare provider awareness is critical for identifying and managing lower grade imAEs. Immediate reporting is important for successfully managing and preventing or worsening of imAEs. Pretreatment sensitization of patients should address barriers to reporting such as fear of ICB discontinuation, ignorance of symptoms, financial constraints, and self-medication. Physicians should rely on clinical presentation and diagnostic work-up (including imaging) to accurately identify, characterize, and differentiate imAEs from metastasis. Treatment-related new symptoms should be dealt with a high level of suspicion. Corticosteroids are initiated if symptoms do not resolve within a week from onset and tapered over a month to avoid rebound of symptoms. ICB therapy should be permanently discontinued in most cases of grade 3-4 imAEs. A multidisciplinary approach involving oncologists, oncosurgeons, primary care physicians, and nurses is necessary in effectively managing imAEs and facilitating better clinical outcomes.
    MeSH term(s) Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/pathology ; Drug-Related Side Effects and Adverse Reactions/therapy ; Humans ; Immunotherapy/adverse effects ; Immunotherapy/methods
    Language English
    Publishing date 2019-12-02
    Publishing country India
    Document type Journal Article ; Review
    ZDB-ID 410194-7
    ISSN 1998-4774 ; 0019-509X
    ISSN (online) 1998-4774
    ISSN 0019-509X
    DOI 10.4103/ijc.IJC_448_19
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 581: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.

    Nag, Shona / Aggarwal, Shyam / Rauthan, Amit / Warrier, Narayanankutty

    Journal of ovarian research

    2022  Volume 15, Issue 1, Page(s) 88

    Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer among women worldwide, with the 5-year survival rate ranging between 30 and 40%. Due to the asymptomatic nature of the condition, it is more likely to be diagnosed at an advanced ... ...

    Abstract Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer among women worldwide, with the 5-year survival rate ranging between 30 and 40%. Due to the asymptomatic nature of the condition, it is more likely to be diagnosed at an advanced stage, requiring an aggressive therapeutic approach. Cytoreductive surgery (CRS) along with systemic chemotherapy with paclitaxel and carboplatin has been the mainstay of the treatment in the frontline management of EOC. In recent years, neo-adjuvant chemotherapy, followed by interval CRS has become an important strategy for the management of advanced EOC. Due to the high rate of recurrence, the oncology community has begun to shift its focus to molecular-targeted agents and maintenance therapy in the frontline settings. The rationale for maintenance therapy is to delay the progression or relapse of the disease, as long as possible after first-line treatment, irrespective of the amount of residual disease. Tumours with homologous recombination deficiency (HRD) including BReast CAncer gene (BRCA) mutations are found to be sensitive to polyadenosine diphosphate-ribose polymerase (PARP) inhibitors and understanding of HRD status has become important in the frontline setting. PARP inhibitors are reported to provide a significant improvement in progression-free survival and have an acceptable safety profile. PARP inhibitors have also been found to act regardless of BRCA status. Recently, PARP inhibitors as maintenance therapy in the frontline settings showed encouraging results in EOC; however, the results from further trials and survival data from ongoing trials are awaited for understanding the role of this pathway in treatment of EOC. This review discusses an overview of maintenance strategies in newly diagnosed EOC along with considerations for maintenance therapy in EOC with a focus on PARP inhibitors.
    MeSH term(s) Carboplatin/therapeutic use ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Female ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
    Chemical Substances Poly(ADP-ribose) Polymerase Inhibitors ; Carboplatin (BG3F62OND5)
    Language English
    Publishing date 2022-07-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2455679-8
    ISSN 1757-2215 ; 1757-2215
    ISSN (online) 1757-2215
    ISSN 1757-2215
    DOI 10.1186/s13048-022-01020-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: High Viral Load and Poor Ventilation: Cause of High Mortality From COVID-19.

    Aggarwal, Shyam / Aggarwal, Shreyas / Aggarwal, Anita / Jain, Kriti / Minhas, Sachin

    Asia-Pacific journal of public health

    2020  Volume 32, Issue 6-7, Page(s) 377–378

    Keywords covid19
    Language English
    Publishing date 2020-07-25
    Publishing country China
    Document type Journal Article
    ZDB-ID 1025444-4
    ISSN 1941-2479 ; 1010-5395
    ISSN (online) 1941-2479
    ISSN 1010-5395
    DOI 10.1177/1010539520944725
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2802: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure.

    Aggarwal, Shyam

    Case reports in oncology

    2015  Volume 8, Issue 3, Page(s) 487–492

    Abstract: The present report illustrates a case of a 37-year-old Indian male patient diagnosed with adenocarcinoma of the sigmoid colon who underwent an anterior resection with total mesorectal excision surgery. He was administered adjuvant chemotherapy with 10 ... ...

    Abstract The present report illustrates a case of a 37-year-old Indian male patient diagnosed with adenocarcinoma of the sigmoid colon who underwent an anterior resection with total mesorectal excision surgery. He was administered adjuvant chemotherapy with 10 cycles of a FOLFOX-4 (folinic acid, fluorouracil and oxaliplatin) regimen but developed relapse. He was then put on a FOLFIRI (folinic acid, fluorouracil and irinotecan)-aflibercept (Zaltrap) regimen and received 12 cycles during the next 6 months. During the treatment period, a reduction in ascites along with a decline in serum carcinoembryonic antigen (CEA) level was observed, though the tumor size was unchanged. After completion of 12 cycles, the patient was asymptomatic but showed signs of progression in the form of increased CEA level. The FOLFIRI-aflibercept therapy was discontinued, and the patient was given supportive treatment, but he eventually died after another 6 months. The FOLFIRI-aflibercept treatment provided a progression-free survival of 6 months and an overall survival of 1 year to this patient, which corroborates the findings of the VELOUR trial.
    Language English
    Publishing date 2015-11-13
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2458961-5
    ISSN 1662-6575
    ISSN 1662-6575
    DOI 10.1159/000441413
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Impact of a National Journal Club and Letter Writing Session on Improving Medical Students' Confidence with Critical Appraisal [Response to Letter].

    Gokani, Shyam Ajay / Sharma, Ekta / Sharma, Tanisha / Moudhgalya, Shyam Venkatesan / Selvendran, Subothini Sara / Aggarwal, Nikhil

    Advances in medical education and practice

    2020  Volume 11, Page(s) 79–80

    Language English
    Publishing date 2020-01-23
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2578539-4
    ISSN 1179-7258
    ISSN 1179-7258
    DOI 10.2147/AMEP.S246428
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Low-MFI (median fluorescence intensity) pre-transplant DSA (donor specific antibodies) leading to anamnestic antibody mediated rejection in live-related donor kidney transplantation.

    Chauhan, Rajni / Tiwari, Aseem Kumar / Aggarwal, Geet / Gowri Suresh, L / Kumar, Mohit / Bansal, Shyam Bihari

    Transplant immunology

    2023  Volume 81, Page(s) 101931

    Abstract: In solid organ transplantation, the compatibility between recipient and donor relies on testing prior to transplantation as a major determinant for the successful transplant outcomes. This compatibility testing depends on the detection of donor-specific ...

    Abstract "In solid organ transplantation, the compatibility between recipient and donor relies on testing prior to transplantation as a major determinant for the successful transplant outcomes. This compatibility testing depends on the detection of donor-specific antibodies (DSAs) present in the recipient. Indeed, sensitized transplant candidates are at higher risk of allograft rejection and graft loss compared to non-sensitized individuals. Most of the laboratories in India have adopted test algorithms for the appropriate risk stratification of transplants, namely: 1) donor cell-based flow-cytometric cross-match (FCXM) assay with patient's serum to detect DSAs; 2) HLA-coated beads to detect anti-HLA antibodies; and 3) complement-dependent cytotoxicity crossmatch (CDCXM) with donor cells to detect cytotoxic antibodies. In the risk stratification strategy, laboratories generally accept a DSA median fluorescence index (MFI) of 1000 MFI or lower MFI (low-MFI) as a negative value and clear the patient for the transplant. We present two cases of live-related donor kidney transplants (LDKTs) with low-MFI pre-transplant DSA values who experienced an early acute antibody-mediated rejection (ABMR) as a result of an anamnestic antibody response by DSA against HLA class II antibodies. These results were confirmed by retesting of both pre-transplant and post-transplant archived sera from patients and freshly obtained donor cells. Our examples indicate a possible ABMR in patients with low MFI pre-transplant DSA. Reclassification of low vs. high-risk may be appropriate for sensitized patients with low-MFI DSA."
    MeSH term(s) Humans ; Kidney Transplantation ; HLA Antigens ; Antibodies ; Tissue Donors ; Histocompatibility Testing/methods ; Kidney ; Graft Rejection ; Isoantibodies ; Retrospective Studies
    Chemical Substances HLA Antigens ; Antibodies ; Isoantibodies
    Language English
    Publishing date 2023-09-18
    Publishing country Netherlands
    Document type Case Reports
    ZDB-ID 1160846-8
    ISSN 1878-5492 ; 0966-3274
    ISSN (online) 1878-5492
    ISSN 0966-3274
    DOI 10.1016/j.trim.2023.101931
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3784: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Amelanotic Melanoma

    Md Ali Osama / Seema Rao / Neha Bakshi / Sonia Badwal / Shyam Aggarwal

    Journal of Laboratory Physicians, Vol 15, Iss 02, Pp 300-

    A Great Masquerader

    2023  Volume 305

    Abstract: Malignant melanoma is an aggressive, notorious tumor showing great variability in morphological and immunohistochemical expression, thus commonly leading to an erroneous diagnosis. Within the melanoma group, amelanotic melanoma, with its wide clinical ... ...

    Abstract Malignant melanoma is an aggressive, notorious tumor showing great variability in morphological and immunohistochemical expression, thus commonly leading to an erroneous diagnosis. Within the melanoma group, amelanotic melanoma, with its wide clinical presentations, lack of pigmentation, and varied histological appearances, has taken on a new persona as a master masquerader. Use of immunohistochemistry in the diagnosis of malignant tumors, including melanoma, is primordial and indispensable. However, the problem gets compounded in scenario of aberrant antigenic expression. The present case posed multiple diagnostic challenges in form of atypical clinical presentation, variant morphology, as well as aberrant antigenic expression. Here, we present the case of a 72-year-old male who, upon his initial presentation, was thought to be sarcomatoid anaplastic plasmacytoma, but 5 months later another biopsy from a different site revealed the actual diagnosis of amelanotic melanoma.
    Keywords amelanotic ; melanoma ; plasmacytoma ; plasma cell neoplasm ; plasmacytoid ; sarcomatoid ; Medicine ; R
    Subject code 570
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer

    Kriti Jain / Deepa Mehra / Nirmal Kumar Ganguly / Rashmi Rana / Surajit Ganguly / Shyam Aggarwal

    Current Medicine Research and Practice, Vol 13, Iss 5, Pp 232-

    2023  Volume 242

    Abstract: Immune checkpoint (IC) therapy has brought a huge revolution in the field of lung cancer treatment over the past decade. It has also revolutionised treatment paradigm and has tremendously improved patient prognosis. IC inhibitors (ICIs) targeting ... ...

    Abstract Immune checkpoint (IC) therapy has brought a huge revolution in the field of lung cancer treatment over the past decade. It has also revolutionised treatment paradigm and has tremendously improved patient prognosis. IC inhibitors (ICIs) targeting Programmed Cell Death Protein 1/Programmed cell death Ligand 1 (PD1/PD-L1) have shown remarkable success and are now being used as first-line therapies in metastatic disease, adjuvant therapy following surgical resection and chemotherapy in resectable disease. Despite this remarkable success, only a subset of patients obtains complete benefit and most patients do not respond or develop progressive disease during treatment. ICIs are relatively expensive and some patients suffer from significant immune-related adverse toxicities. Hence, the identification and discovery of new predictive and prognostic immunotherapy biomarkers remains the present crucial need for patient selection, stratification and also for guiding therapeutic decisions. Currently established biomarkers such as PD-L1 determined by immunohistochemistry and tumour mutation burden determined by next-generation sequencing are non-specific and possess limitations. At present, several other biomarkers using peripheral blood, liquid biopsies along with gene expression signatures, and tumour infiltrating lymphocytes are being researched globally which have demonstrated predictive potential to characterise ICIs responders. In this review, we provide a comprehensive overview of the current biomarkers, highlighting the main clinical challenges and possible novel potential biomarkers to better predict responders to ICIs.
    Keywords biomarkers ; immune checkpoint inhibitors ; immunotherapy ; lung cancer ; pd-1/pd-l1 antibodies ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2023-01-01T00:00:00Z
    Publisher Wolters Kluwer Medknow Publications
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article: Editorial.

    Parikh, Purvish M / Aggarwal, Shyam / Hingmire, Sachin

    South Asian journal of cancer

    2018  Volume 7, Issue 2, Page(s) 67–68

    Language English
    Publishing date 2018-04-18
    Publishing country India
    Document type Editorial
    ZDB-ID 2719571-5
    ISSN 2278-4306 ; 2278-330X
    ISSN (online) 2278-4306
    ISSN 2278-330X
    DOI 10.4103/sajc.sajc_144_18
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top